| P/E (FY) | 12.9 | Sales (TTM) | €493.6M |
| Earnings (TTM) | €111.4M | ROE | 16.04% |
| Net Margin | 22.56% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 9.66% | Sales Growth 3Y | 7.39% |
Faes Farma, S.A. researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments, and its activities also extend to foodstuffs, cosmetics, dietetics, and medicinal plants. The company offers products across various therapeutic areas. It was incorporated in 1933 and is headquartered in Leioa, Spain.
| Market Cap | $1.63B | Trading Days | 4190 |
| 52W High | 5.44 |
| 52W Low | 4.10 |
| % Off High | −15.35% |
| YTD | −8.32% | 1Y | 6.79% |
| 3Y | 56.76% | 5Y | 69.42% |
| 10Y | 93.17% | Since incept. (ann.) | 4.98% |
| Ann. Volatility (1Y) | 20.58% | Ann. Volatility (3Y) | 19.66% |
| Sharpe (1Y) | 0.42 | Sharpe (3Y) | 0.87 |
| Max Drawdown (1Y) | −17.23% | Max Drawdown (3Y) | −17.23% |
| Beta (3Y, vs SPY) | 0.11 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SLN | Silence Therapeutics plc | $1.64B | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.64B | — |
| ABCL | AbCellera Biologics Inc. | $1.65B | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.61B | — |
| HCSG | HEALTHCARE SERVICES GROUP INC | $1.61B | 28.9 |
| ZYME | Zymeworks Inc. | $1.61B | — |
| TDOC | Teladoc Health, Inc. | $1.66B | — |
| INVA | Innoviva, Inc. | $1.60B | 6.6 |
| GENB | Generate Biomedicines, Inc. | $1.68B | — |
| ALMR | Alamar Biosciences, Inc. | $1.69B | — |
| ARDT | Ardent Health, Inc. | $1.57B | 11.4 |
| PHM.MC | PHARMA MAR, S.A. | $1.57B | 52.7 |
